Nucleic Acid Therapeutics · 2013 · 15 citations · 24 references
PharmacyMedicinal ChemistryMolecular BiologyAntibody EngineeringDrug DeliveryMonoclonal AntibodiesAntibody ConjugatesAntibody ConjugationAntibody PharmacokineticsMonoclonal Antibody TherapyPharmacokinetics Of Monoclonal AntibodiesTherapeutic Monoclonal AntibodiesAntibody Targeting LigandsConjugated OligonucleotidesMonoclonal Antibody DesignMonoclonal Antibody TherapeuticsOligonucleotide HybridizationOligonucleotide TherapeuticsRituximab-based TherapyRna Hybridization
Monoclonal antibodies (mAbs) have naturally evolved as suitable, high affinity and specificity targeting molecules. However, the large size of full-length mAbs yields poor pharmacokinetic properties. A solution to this issue is the use of a multistep administration approach, in which the slower clearing mAb is administered first and allowed to reach the target site selectively, followed by administration of a rapidly clearing small molecule carrier of the cytotoxic or imaging ligand, which bears a cognate receptor for the mAb. Here, we introduce a novel pretargetable RNA based system comprised of locked nucleic acids (LNA) and 2'O-Methyloligoribonucleotides (2'OMe-RNA). The duplex shows fast hybridization, high melting temperatures, excellent affinity, and high nuclease stability in plasma. Using a prototype model system with rituximab conjugated to 2'OMe-RNA (oligo), we demonstrate that LNA-based complementary strand (c-oligo) effectively hybridizes with rituximab-oligo, which is slowly circulating in vivo, despite the high clearance rates of c-oligo.
24
IDT SciTools: a suite for analysis and design of nucleic acid oligomers
Richard Owczarzy, Andrey V. Tataurov, Yanfei Wu et al. · Nucleic Acids Research · 2008 · 546 citations · Full text